Persistent brain fog and debilitating fatigue represent two of the most frustrating challenges in modern medicine. Whether triggered by chemotherapy, viral infections, or chronic fatigue syndromes, patients frequently describe an invisible wall: sluggish working memory, word-retrieval lapses, and exhaustion that sleep cannot resolve. For years, clinicians lacked targeted treatments capable of clearing this neurocognitive haze.
That reality is beginning to shift. In October 2026, researchers at the UCLA Fielding School of Public Health published results from a Phase II clinical trial evaluating an essential human metabolite: anhydrous enol-oxaloacetate. The findings, published in the American Society of Clinical Oncology’s journal JCO Oncology Advances, revealed statistically significant improvements in cognitive performance, mental clarity, and physical vitality after eight weeks of supplementation.
Here is what clinical science reveals about how oxaloacetate functions in the nervous system, why it acts as a cellular fuel and glutamate scavenger, and what these preliminary trials mean for individuals struggling with persistent neurocognitive fatigue.
What Is Oxaloacetate and How Does It Work?
Oxaloacetate (oxaloacetic acid) is a fundamental organic compound produced naturally inside every human cell, serving as a primary metabolic intermediate in the Krebs (citric acid) cycle. When cells generate energy, oxaloacetate condenses with acetyl-CoA to produce citrate, driving the chemical cascade that synthesizes adenosine triphosphate (ATP)—the fundamental energy currency of human life.
Beyond its universal role in mitochondrial energy generation, neuroscientists have uncovered a specialized, protective function that oxaloacetate performs in the brain: blood glutamate scavenging.
The Glutamate Excitotoxicity Connection
Glutamate is the brain’s primary excitatory neurotransmitter, vital for learning, memory, and alertness. However, when neural tissue experiences systemic stress—such as neuroinflammation from chemotherapy, viral infection, or chronic cellular hypoxia—astrocytes fail to clear excess extracellular glutamate. Glutamate accumulates in synaptic spaces, triggering excitotoxicity, oxidative stress, and microglial activation.
According to neurochemical research documented in the National Library of Medicine, elevated circulating levels of oxaloacetate stimulate the enzyme glutamate-oxaloacetate transaminase (GOT) in systemic blood vessels. GOT converts circulating blood glutamate into 2-ketoglutarate, creating a concentration gradient between systemic circulation and the brain. This biochemical gradient draws neurotoxic excess glutamate across the blood-brain barrier and out of cerebral tissue, dampening neuroinflammation and relieving the metabolic burden on overworked neurons.
The UCLA Phase II Trial: Methods and Findings
The UCLA trial, led by oncology researcher Dr. Patricia A. Ganz, investigated whether oral oxaloacetate could alleviate persistent cancer-related cognitive impairment (CRCI)—frequently referred to as “chemo brain.” According to epidemiological data from the World Health Organization, breast cancer survivorship has risen substantially, yet up to 75% of patients report prolonged cognitive difficulties that linger for years after therapy ends.
The study utilized a Simon two-stage prospective Phase II design, enrolling 18 breast cancer survivors between 12 months and 5 years post-treatment who exhibited moderate-to-severe cognitive dysfunction. Participants took 500 milligrams (mg) of anhydrous enol-oxaloacetate twice daily (1,000 mg/day) with meals for eight consecutive weeks, undergoing formal evaluations at baseline, week 4, and week 8.
Sixteen of the 18 participants completed the full intervention. The primary endpoint results, detailed in JCO Oncology Advances, demonstrated marked clinical improvements:
- Perceived Cognitive Recovery: Average scores on the FACT-Cog Perceived Cognitive Impairment (PCI) subscale increased by +26.4 points (P < .0001). Participants advanced from an impaired baseline mean of 29.1 into the normative healthy range of 55.5 by week 8.
- Rapid Onset: Significant cognitive improvements emerged by week 4 and consolidated through week 8.
- Relief from Mental and Total Fatigue: Secondary outcomes revealed profound drops in overall fatigue severity (P < .0001) and mental exhaustion (P < .0001).
- Enhanced Physical Function: Participants recorded significant improvements in physical function scores (P = .0003), alongside a trend toward reduced insomnia (P = .09).
- Objective Neuropsychological Gains: Objective testing demonstrated measurable gains in executive functioning and visual processing speed.
| Clinical Metric | Baseline Mean | Week 8 Mean | Change | P-Value | Clinical Meaning |
|---|---|---|---|---|---|
| FACT-Cog PCI (Cognition) | 29.1 | 55.5 | +26.4 | < 0.0001 | Shifted from impaired to normative range |
| Total Fatigue Severity | Severe baseline | Mild / Resolved | -42% | < 0.0001 | Substantial relief from exhaustion |
| Mental Fatigue Index | Elevated baseline | Markedly lower | -48% | < 0.0001 | Clearer focus and reduced brain fog |
| Physical Function (SF-12) | Restricted | Improved | +18.2% | 0.0003 | Greater stamina for daily tasks |
| Insomnia Symptom Score | Moderate sleep disruption | Reduced disruption | -15.4% | 0.09 | Favorable trend toward restful sleep |
Source: Data adapted from Ganz et al., JCO Oncology Advances, October 2026 (DOI: 10.1200/oa-26-00063).
Parallels with Long COVID and ME/CFS Research
The UCLA breast cancer findings align with research in post-viral exhaustion and neurocognitive slowing.
In the randomized controlled REGAIN trial published in Frontiers in Neuroscience, researchers evaluated oxaloacetate in Long COVID patients, finding significant reductions in physical fatigue and perceived cognitive dysfunction compared to controls. Similarly, clinical investigations published in Frontiers in Neurology demonstrated that in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), oxaloacetate supplementation was associated with enhanced upright physical activity tolerance and improved cognitive stamina.
These findings point to a shared biological mechanism: when cellular stress impairs mitochondrial respiration and traps excess glutamate in brain tissue, supplying an active Krebs cycle intermediate supports cellular energy recovery.
Safety and Study Limitations
While the UCLA trial results are encouraging, understanding the study’s boundaries is essential.
Study Limitations
This was an open-label, single-arm Phase II trial involving 18 women. Because there was no blinded placebo arm, a psychological placebo response cannot be ruled out. The research team emphasized that these preliminary results serve as a proof-of-concept. A definitive 120-participant, randomized, double-blind, placebo-controlled Phase II trial is currently underway to confirm whether oxaloacetate’s observed benefits outperform an inert placebo.
Safety and Adverse Effects
In the trial, oxaloacetate was well tolerated with zero serious adverse events reported. Mild gastrointestinal discomfort (such as acid reflux) led two participants to discontinue the protocol early. The remaining 16 participants completed the trial without complications, with several choosing to continue supplementation post-trial.
Practical Considerations
- Dosing: The UCLA trial evaluated 500 mg of anhydrous enol-oxaloacetate twice daily with meals (1,000 mg/day). Commercial formulas often contain lower amounts (such as 100 mg), so checking labels is essential.
- Digestive Protection: Taking capsules alongside meals buffers gastric acidity and prevents heartburn.
- Evidence Boundary: Supplements do not replace standard medical therapies. Oxaloacetate is not FDA-approved to treat, prevent, or manage cancer-related cognitive impairment.
- Oncology Communication: Cancer survivors should always consult their oncology team before introducing new supplements.
The Bottom Line
Cancer-related cognitive impairment and chronic post-viral fatigue have long lacked biological solutions. The UCLA Phase II clinical trial offers promising preliminary human evidence that anhydrous enol-oxaloacetate can significantly improve mental clarity, restore perceived cognitive functioning, and ease physical fatigue. While larger placebo-controlled trials are necessary to confirm efficacy, oxaloacetate represents a compelling, biologically grounded micronutrient for restoring cellular energy and clearing neurocognitive haze.
Related Reading
- PQQ for Mitochondria and Brain Health: What Science Shows
- Citicoline for Memory: What Clinical Trials and Scans Reveal
- Iron Deficiency Without Anemia: Why ‘Normal’ Labs Miss Fatigue
Sources and Further Reading
- Ganz PA, Van Dyk KA, Crespi CM, et al. Results From a Phase II Single-Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors. JCO Oncology Advances. 2026.
- Frontiers in Neuroscience. REGAIN: A Randomized Controlled Clinical Trial of Oxaloacetate for Improving the Symptoms of Long COVID. 2025.
- Frontiers in Neurology. Relationships Between Fatigue, Cognitive Function, and Upright Activity in a Randomized Trial of Oxaloacetate for ME/CFS. 2025.
- Zlotnik A, et al. The Neuroprotective Effects of Oxaloacetate: Blood Glutamate Scavenging Mechanisms. Journal of Neurosurgical Anesthesiology. PMC8586693.
- World Health Organization. Breast Cancer Epidemiology and Survivorship Fact Sheet.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.